Trials / Active Not Recruiting
Active Not RecruitingNCT05919147
The Neuroendocrine Effects of Pioglitazone in Patients With Cancer and Cachexia
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Neuroendocrine Effects of Pioglitazone in Patients With Cancer and Cachexia
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 24 (estimated)
- Sponsor
- Pennington Biomedical Research Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The goal of this clinical trial is evaluate the effect of pioglitazone compared with placebo on skeletal muscle insulin sensitivity in subjects with cancer and cachexia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pioglitazone 45 mg | The dose of pioglitazone will not exceed 45 mg once daily. Pioglitazone dose will titrate progressively over the first three weeks. |
| DRUG | Placebo | Placebo will have the same appearance as the active drug. |
Timeline
- Start date
- 2024-01-03
- Primary completion
- 2025-06-30
- Completion
- 2026-06-30
- First posted
- 2023-06-26
- Last updated
- 2025-07-04
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05919147. Inclusion in this directory is not an endorsement.